Journal ArticleDOI
Modelling the economic and clinical burden of non‐alcoholic steatohepatitis in East Asia: Data from Hong Kong
Radhika P. Tampi,Vincent Wai-Sun Wong,Grace Lai-Hung Wong,Sally She-Ting Shu,Henry Lik-Yuen Chan,James Fung,Maria Stepanova,Zobair M. Younossi,Zobair M. Younossi +8 more
Reads0
Chats0
TLDR
Non‐alcoholic steatohepatitis (NASH) is the progressive form of non-alcoholic fatty liver disease (NAFLD) and prevalence is rising in Asia due to increasing rates of urbanization, sedentary lifestyles, and poor nutrition.About:
This article is published in Hepatology Research.The article was published on 2020-06-14. It has received 38 citations till now. The article focuses on the topics: Population & Steatohepatitis.read more
Citations
More filters
Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study
Eduardo Vilar-Gomez,Eduardo Vilar-Gomez,Luis Calzadilla-Bertot,Vincent Wai-Sun Wong,Marlen Castellanos,Rocio Aller-de la Fuente,Mayada Metwally,Mohammed Eslam,Licet Gonzalez-Fabian,María Alvarez-Quiñones Sanz,Antonio Felix Conde-Martin,Bastiaan De Boer,Duncan McLeod,Anthony W.H. Chan,Naga Chalasani,Jacob George,Leon A. Adams,Manuel Romero-Gómez +17 more
TL;DR: In this paper, the authors describe long-term outcomes and evaluate the effects of clinical and histologic parameters on disease progression in patients with advanced nonalcoholic fatty liver disease (NAFLD) with bridging fibrosis.
The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases
Naga Chalasani,Zobair M. Younossi,Joel E. Lavine,Michael Charlton,Kenneth Cusi,Mary E. Rinella,Stephen A. Harrison,Elizabeth M. Brunt,Arun J. Sanyal +8 more
TL;DR: The Grading of Recommendations, Assessment Development, and Evaluation (GRADE) system as discussed by the authors provides a data-supported approach to the diagnostic, therapeutic, and preventive aspects of NAFLD care.
Journal ArticleDOI
Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease?
TL;DR: Given the association of NAFLD with metabolic risks, a name change to MAFLD is proposed and the long‐term outcomes ofNAFLD andMAFLD are compared.
Journal ArticleDOI
Are There Outcomes Differences Between Non-alcoholic Fatty Liver Disease (NAFLD) and Metabolic Associated Fatty Liver Disease (MAFLD)?
TL;DR: MAFLD and NAFLD have similar clinical profiles and long-term outcomes and the increased liver-related mortality among NAFLd is driven by IR and among MAFLD is primarily driven by ALD.
Journal ArticleDOI
Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world
TL;DR: The global prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing in parallel with obesity and type 2 diabetes as mentioned in this paper , however, NAFLD awareness remains low among patients and healthcare providers.
References
More filters
Journal ArticleDOI
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
Zobair M. Younossi,Zobair M. Younossi,Aaron B. Koenig,Dinan Abdelatif,Yousef Fazel,Linda Henry,Mark Wymer,Mark Wymer +7 more
TL;DR: As the global epidemic of obesity fuels metabolic conditions, the clinical and economic burden of NAFLD will become enormous, and random‐effects models were used to provide point estimates of prevalence, incidence, mortality and incidence rate ratios.
Journal ArticleDOI
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani,Zobair M. Younossi,Joel E. Lavine,Michael Charlton,Kenneth Cusi,Mary E. Rinella,Stephen A. Harrison,Elizabeth M. Brunt,Arun J. Sanyal +8 more
TL;DR: This guidance provides a data-supported approach to the diagnostic, therapeutic, and preventive aspects of NAFLD care.
Journal ArticleDOI
New trends on obesity and NAFLD in Asia
TL;DR: The epidemiological trend of obesity in Asia is reviewed, with special emphasis on the emerging condition of non-alcoholic fatty liver disease (NAFLD), and pharmacological agents have entered phase III development for steatohepatitis.
Journal ArticleDOI
Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years
Vincent Wai-Sun Wong,Grace Lai-Hung Wong,Paul Cheung-Lung Choi,Anthony W.H. Chan,Mia Ka-Po Li,Hoi-Yun Chan,Angel Mei-Ling Chim,Jun Yu,Joseph J.Y. Sung,Henry Lik-Yuen Chan +9 more
TL;DR: Investigating disease progression in patients with different degrees of non-alcoholic fatty liver disease (NAFLD) activity found weight reduction is associated with non-progressive disease and fibrosis.
Journal ArticleDOI
Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis
Jie Li,Jie Li,Biyao Zou,Yee Hui Yeo,Yuemin Feng,Xiaoyu Xie,Dong Hyun Lee,Hideki Fujii,Yuankai Wu,Yuankai Wu,Leslie Y. Kam,Fanpu Ji,Fanpu Ji,Xiaohe Li,Nicholas Chien,Mike Wei,Eiichi Ogawa,Eiichi Ogawa,Changqing Zhao,Xia Wu,Xia Wu,Christopher D Stave,Linda Henry,Scott D. Barnett,Hirokazu Takahashi,Norihiro Furusyo,Yuichiro Eguchi,Yao-Chun Hsu,Teng-Yu Lee,Wanhua Ren,Chengyong Qin,Dae Won Jun,Hidenori Toyoda,Vincent Wai-Sun Wong,Ramsey Cheung,Ramsey Cheung,Qiang Zhu,Mindie H. Nguyen +37 more
TL;DR: NAFLD prevalence in Asia is increasing and is associated with poor outcomes including hepatocellular carcinoma and death, especially in high-risk groups, such as older obese men, and targeted public health strategies must be developed in Asia.